Skip to main content
. 2024 Nov 30;67(23):21486–21504. doi: 10.1021/acs.jmedchem.4c02366

Figure 4.

Figure 4

SHO1122147 is an orally bioavailable protonophore. (A) Pharmacokinetic properties of SHO1122147 administered to C57BL/6J male mice by oral gavage at 10 mg kg–1 (n = 3). (B) Dose–response curves of SHO1122147 and BAM15-stimulated L6 myoblast cells. (C) Mitochondrial stress test in L6 myoblast cells dosed sequentially with oligomycin (oligo, 1 μM) or vehicle, SHO1122147 (10 μM) or BAM15 (1.1 μM) with vehicle, and antimycin A (AntA, 10 μM) plus rotenone (rot, 1 μM) at the indicated time. n = 3 wells per condition. Values are represented as mean ± standard error of the mean (SEM) (D) Self-limiting test in L6 myoblast cells–dosed with SHO1122147 (10 μM) followed by BAM15 (1.1 μM) and antimycin A (AntA, 10 μM) plus rotenone (Rot, 1 μM) were added at the indicated time. n = 4 wells per condition from three separate experiments.